Advertisement
Advertisement

Read Now: News and Research From IDWeek 2014

HIV MANAGEMENT IN DEPTH

An interview series exploring key issues in HIV care.

John Steever, M.D.Key Issues Affecting the Care of HIV-Positive Adolescents
An Interview With John Steever, M.D.

Edward Machtinger, M.D.Unraveling the Impact of Trauma on People With HIV -- and Their Care Providers
An Interview With Edward Machtinger, M.D.

Mark HarringtonThe Future of HIV Prevention, Treatment and Care
An Interview With Mark Harrington

David Alain Wohl, M.D.New HIV Heart Disease Findings Not as Dire as They May Seem
An Interview With David Alain Wohl, M.D.

David Harrich, Ph.D.How to Make HIV "Take Up Knitting"
An Interview With David Harrich, Ph.D.

HIV CARE TODAY

A blog featuring professionals on the frontlines of HIV treatment, prevention and care.

Paul E. Sax, M.D.Approval of Sofosbuvir/Ledipasvir Was Expected, but Still Is a Huge Advance
A Blog Entry by Paul E. Sax, M.D.

Paul E. Sax, M.D.New FDA HIV Drug Approvals Unlikely to Have Much Impact, Unless ...
A Blog Entry by Paul E. Sax, M.D.

Paul E. Sax, M.D.Quick Question: How Do I Fill Out This Tricky Patient Job or School Form?
A Blog Entry by Paul E. Sax, M.D.

Monica Gomes, M.D., M.Sc.Could an Integrase Inhibitor Have Prevented One More HIV Infection?
A Blog Entry by Monica Gomes, M.D., M.Sc.

Howard Grossman, M.D.Health Insurance Companies Are the Biggest Impediment to PEP and PrEP for HIV Prevention
A Blog Entry by Howard Grossman, M.D.

HIV/AIDS NEWSROOM

IDWeek 2014: Viral Rebound Is Significantly Delayed Among Some Who Interrupt HIV Treatment

IDWeek 2014: Intensive Intervention Re-Engages Patients Lost to Care in Inner-City Philadelphia Clinic

IDWeek 2014: Factors Associated With 10 Years of Continuous Viral Load Suppression on HIV Treatment

IDWeek 2014: Preventing and Treating HIV-Associated Bone Disease

ICAAC 2014: Challenges to Stem Cell Transplantation in HIV-Positive Patients

ICAAC 2014: Cardiovascular Disease Risk Missed in Many HIV-Positive Veterans Despite Better Risk-Assessment Tool

Antiretroviral Studies at ICAAC 2014: Darunavir-Based FDC With TAF, Cobicistat, Doravirine, Stribild and Gel Formulation PrEP

ICAAC 2014: Switch From Efavirenz to Rilpivirine Quells CNS Toxicity, Improves Sleep

ICAAC 2014: Only 10 Percent of Veterans With HCV or HCV/HIV in the U.S. Treated for HCV

Stemming the Flow From HIV Reservoirs With Neutralizing Antibodies

Case Report: Stem Cell Transplantation From CCR5 Delta-32 Homozygous Donor Selects for X4-Tropic HIV

Kidney Signal Trouble Worsens Over 5 Years in Japanese on Tenofovir

U.K. Updates PEP Guidelines: Raltegravir Replaces PIs and No Indication if Positive Partner Has an Undetectable Viral Load

ICAAC 2014: Long-Acting, Investigational Integrase Inhibitor Cabotegravir Shows Promise



Advertisement